Nurix Therapeutics, Inc.

NasdaqGM:NRIX 株式レポート

時価総額：US$1.8b

Nurix Therapeutics マネジメント

マネジメント 基準チェック /34

Nurix Therapeuticsの CEO はArthur Sandsで、 Sep2014年に任命され、 の在任期間は 11.67年です。 の年間総報酬は$ 6.37Mで、 10.6%給与と89.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.3%を直接所有しており、その価値は$ 5.41M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と4.1年です。

主要情報

Arthur Sands

最高経営責任者

US$6.4m

報酬総額

CEO給与比率10.58%
CEO在任期間11.7yrs
CEOの所有権0.3%
経営陣の平均在職期間5.8yrs
取締役会の平均在任期間4.1yrs

経営陣の近況

分析記事 • May 12

Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being

Key Insights Nurix Therapeutics' Annual General Meeting to take place on 19th of May CEO Arthur Sands' total...

Recent updates

Seeking Alpha • Apr 09

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

Summary Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies. While cash reserves stand at $540.7M, NRIX faces a 12-month runway and will require additional funding to sustain its R&D-intensive pipeline. Read the full article on Seeking Alpha
分析記事 • Nov 16

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders have had their patience rewarded with a 30% share price jump in...
分析記事 • Oct 12

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) missed earnings with its latest quarterly results, disappointing...
分析記事 • Sep 30

Subdued Growth No Barrier To Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price

With a median price-to-sales (or "P/S") ratio of close to 10x in the Biotechs industry in the United States, you could...
分析記事 • Aug 18

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

NasdaqGM:NRIX 1 Year Share Price vs Fair Value Explore Nurix Therapeutics's Fair Values from the Community and select...
分析記事 • Jul 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • May 12

Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being

Key Insights Nurix Therapeutics' Annual General Meeting to take place on 19th of May CEO Arthur Sands' total...
Seeking Alpha • Apr 17

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Summary FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $135 million from its Gilead collaboration and could earn up to a total of $420 million in milestone payments for developing up to five protein degraders. Nurix's wholly owned BTK degrader Bexobrutideg is in phase 1b trials for relapsed/refractory B-cell malignancies, with plans to target inflammatory and autoimmune disorders as well. Besides the partnership with Gilead Sciences, the company is advancing its STAT6 protein degrader with Sanofi and antibody drug conjugate degraders as a new class of drugs to target disorders with Pfizer. Read the full article on Seeking Alpha
分析記事 • Apr 17

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • Mar 22

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has dived 25% in the last...
Seeking Alpha • Feb 18

Nurix Therapeutics: A Story To Monitor

Summary Nurix Therapeutics, Inc.'s shares have dropped some 40% due to limited 2025 data catalysts, despite promising Phase 1 results for NX-5948 in CLL, targeting pivotal trials in 2025. Nurix's DELigase platform leverages E3 ligases for protein modulation, aiming to degrade or elevate proteins, offering advantages over CRISPR and RNA interference methods. NX-5948 shows strong efficacy in heavily pre-treated CLL patients, with Fast Track and PRIME designations, but faces competition from BeiGene's similar BTK degrader. An initial analysis around NRIX stock follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Jan 30

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Nurix Therapeutics...
Seeking Alpha • Jan 05

Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me

Summary Nurix Therapeutics (NRIX) focuses on protein degradation in cancer treatment, with a current valuation of $1.4 billion and promising early-stage clinical data. NX-5948, a BTK degrader, shows high response rates in B-cell malignancies, with manageable safety profiles and FDA Fast Track designations. Financially, NRIX holds $99 million in cash and $349 million in marketable securities, but faces risks of future dilution and high execution expectations. Despite compelling early data, NRIX's high valuation and market hype suggest waiting for better entry points, making it a "Hold" for now, in my opinion. Read the full article on Seeking Alpha
分析記事 • Nov 07

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Despite an already strong run, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have been powering on, with a gain of...
分析記事 • Oct 31

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Nurix...
Seeking Alpha • Oct 08

Nurix: An Attractive Early-Stage Biotech Play

Summary Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain. Nurix's innovative approach and potential regulatory approvals make it a strong investment candidate for those seeking high-risk, high-reward opportunities. Read the full article on Seeking Alpha
分析記事 • Sep 07

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics, Inc.'s ( NASDAQ:NRIX ) price-to-sales (or "P/S") ratio of 24.1x might make it look like a strong...
Seeking Alpha • Sep 04

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Summary Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key programs include BTK, IKZF, and CBL-B targets, with notable molecules NX-5948, NX-2127, and NX-1607 showing potential in heavily pretreated B-cell malignancies. Strategic partnerships with Gilead, Sanofi, and Pfizer provide substantial financial backing, with up to $8.1 billion in potential milestone payments. Despite high valuation and limited near-term data catalysts, Nurix's innovative approach and big pharma interest warrant continued observation for future investment opportunities. Read the full article on Seeking Alpha
分析記事 • Jul 15

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, Nurix Therapeutics...
Seeking Alpha • Jun 19

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Summary Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional small molecules. Nurix's lead proprietary candidate NX-5948 showed promising results in a Phase 1a clinical study for CLL patients in data released this week, triggering a surge in the company's share price. Management hopes to guide its lead candidate into a pivotal study next year, opening up a potentially compelling market opportunity. More data - in NHL and immuno-oncology - will arrive this year, and Nurix continues to collaborate with three major Pharma companies - Gilead, Sanofi, and Pfizer. The bull run can therefore be sustained. Read the full article on Seeking Alpha
分析記事 • May 29

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

The Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has done very well over the last month, posting an excellent...
Seeking Alpha • Apr 15

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Summary Nurix Therapeutics raises $175 million in an upsized offering after a 168% stock return in the past six months. The biotech company is developing protein degraders, with NX-2127 and NX-5948, targeting B-cell malignancies. Nurix's protein degraders are focused on BTK, a target also addressed by Johnson & Johnson's popular drug Imbruvica. Hold rating advised: High-risk, high-reward due to innovative approach and competitive market; efficacy and safety data needed. Read the full article on Seeking Alpha
分析記事 • Apr 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have continued their recent momentum with a 28% gain in the last month...
分析記事 • Feb 20

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 6.3x Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be sending very bullish...
Seeking Alpha • Jan 16

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Summary Nurix Therapeutics remains a highly interesting science project, but the rubber has yet to hit the road on their clinical projects. The company's BTK degraders are showing early signs of life, but the competition in the market and expenses are concerns. Nurix has enough assets to fund operations for another 6 to 7 quarters, but a cash infusion may be needed later this year. Read the full article on Seeking Alpha
分析記事 • Dec 29

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Oct 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

To the annoyance of some shareholders, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares are down a considerable 29% in...
分析記事 • Oct 13

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Shareholders in Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be thrilled to learn that the analysts have just delivered...
分析記事 • Sep 30

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Apr 18

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • Apr 15

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Nov 28

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO報酬分析

Nurix Therapeutics の収益と比較して、Arthur Sands の報酬はどのように変化したか？
日付総報酬給与会社業績
Feb 28 2026n/an/a

-US$295m

Nov 30 2025US$6mUS$675k

-US$264m

Aug 31 2025n/an/a

-US$245m

May 31 2025n/an/a

-US$207m

Feb 28 2025n/an/a

-US$208m

Nov 30 2024US$6mUS$613k

-US$194m

Aug 31 2024n/an/a

-US$177m

May 31 2024n/an/a

-US$165m

Feb 29 2024n/an/a

-US$145m

Nov 30 2023US$4mUS$591k

-US$144m

Aug 31 2023n/an/a

-US$149m

May 31 2023n/an/a

-US$157m

Feb 28 2023n/an/a

-US$179m

Nov 30 2022US$9mUS$572k

-US$180m

Aug 31 2022n/an/a

-US$171m

May 31 2022n/an/a

-US$154m

Feb 28 2022n/an/a

-US$135m

Nov 30 2021US$5mUS$539k

-US$117m

Aug 31 2021n/an/a

-US$99m

May 31 2021n/an/a

-US$89m

Feb 28 2021n/an/a

-US$63m

Nov 30 2020US$17mUS$521k

-US$43m

Aug 31 2020n/an/a

-US$37m

May 31 2020n/an/a

-US$21m

Feb 29 2020n/an/a

-US$24m

Nov 30 2019US$1mUS$474k

-US$22m

報酬と市場: Arthurの 総報酬 ($USD 6.37M ) は、 US市場 ($USD 5.48M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Arthurの報酬は増加しましたが、会社は利益を上げていません。

CEO

Arthur Sands (63 yo)

11.7yrs
在職期間
US$6,374,138
報酬

Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Arthur Sands
CEO, President & Director11.7yrsUS$6.37m0.30%
$ 5.4m
Johannes Van Houte
Chief Financial Officer10.2yrsUS$2.30m0.036%
$ 658.9k
Gwenn Hansen
Chief Scientific Officer5.9yrsUS$2.50m0.12%
$ 2.1m
Christine Ring
Chief Legal Officer6.7yrsUS$2.26m0.018%
$ 320.8k
John Kuriyan
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Arthur Weiss
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Rita Kwong
Senior Accounting Managerno dataデータなしデータなし
Pasit Phiasivongsa
Chief Technical Officer2yrsデータなしデータなし
Jason Kantor
Chief Business Officer5.8yrsデータなしデータなし
Christopher Phelps
Senior VP & Head of Early Drug Discovery5.3yrsデータなしデータなし
Buckley Kohlhauff
Senior Vice President of Information Technology4.3yrsデータなしデータなし
Bev Benson
VP & Head of Clinical Science4.3yrsデータなしデータなし
5.8yrs
平均在職期間
59yo
平均年齢

経験豊富な経営陣: NRIXの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。

取締役

名称ポジション在職期間報酬所有権
Arthur Sands
CEO, President & Director11.7yrsUS$6.37m0.30%
$ 5.4m
John Kuriyan
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Arthur Weiss
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Julia Gregory
Independent Chairman6.8yrsUS$258.97k0.010%
$ 188.5k
Ronald Levy
Member of Medical Advisory Board3.3yrsデータなしデータなし
Judith Reinsdorf
Independent Director4.6yrsUS$229.07k0%
$ 0
Roy Baynes
Independent Director1.2yrsUS$668.79k0%
$ 0
David Lacey
Independent Director10.1yrsUS$226.57k0.032%
$ 584.4k
Paul Silva
Independent Director4.6yrsUS$230.32k0%
$ 0
Edward Saltzman
Independent Director3.7yrsUS$220.22k0%
$ 0
Roger Dansey
Independent Directorless than a yearUS$421.68kデータなし
Anil Kapur
Independent Director1.6yrsUS$217.93k0%
$ 0
4.1yrs
平均在職期間
69yo
平均年齢

経験豊富なボード: NRIXの 取締役会 は 経験豊富 であると考えられます ( 4.1年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/22 23:45
終値2026/05/22 00:00
収益2026/02/28
年間収益2025/11/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Nurix Therapeutics, Inc. 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25

アナリスト機関
Brian SkorneyBaird
Joel BeattyBaird
Zhiqiang ShuBerenberg